

Application No. 10/028,415

Amendment and Reply to Office Action mailed November 10, 2005

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (withdrawn): A method for modulating apoptotic cell death in a population of cells, comprising modulating the amount of a transcriptional regulator of apoptosis available to bind to a target polynucleotide in the cells, wherein the transcriptional regulator of apoptosis is a member of the Y-box nucleic acid binding family of polypeptides.

Claim 2 (withdrawn): The method of claim 1, wherein the transcriptional regulator of apoptosis comprises an amino acid sequence selected from the group consisting of:

- (a) SEQ ID NO: 39;
- (b) sequences having at least 75% identity to SEQ ID NO: 39; and
- (c) sequences having at least 90% identity to SEQ ID NO: 39.

Claim 3 (withdrawn): The method of claim 1, wherein the transcriptional regulator of apoptosis comprises an amino acid sequence selected from the group consisting of:

- (a) SEQ ID NO: 40;
- (b) sequences having at least 75% identity to SEQ ID NO: 40; and
- (c) sequences having at least 90% identity to SEQ ID NO: 40.

Claims 4 and 5 (canceled).

Claim 6 (previously presented): A method for increasing apoptotic cell death in a population of cells, comprising reducing the amount of a transcriptional regulator of apoptosis available to bind to a target polynucleotide in the cells by contacting the population of cells with an anti-sense oligonucleotide directed against the transcriptional regulator of apoptosis, wherein the transcriptional regulator of apoptosis comprises an amino acid sequence selected from the group consisting of: SEQ ID NO: 39 and 40 and wherein reducing the amount of the transcriptional

Application No. 10/028,415
Amendment and Reply to Office Action mailed November 10, 2005

regulator of apoptosis available to bind to the target polynucleotide leads to an increase in apoptotic cell death.

Claims 7 and 8 (canceled).

Claim 9 (original): The method of claim 6, wherein the cells are tumor cells.

Claims 10-23 (canceled).

Claim 14 (previously presented): A method for increasing p53-mediated apoptosis in a cell population, comprising reducing the amount of a transcriptional regulator of apoptosis available to bind to a target polynucleotide in the cells by contacting the population of cells with an anti-sense oligonucleotide directed against the transcriptional regulator of apoptosis, thereby increasing expression of p53 and increasing p53-mediated apoptosis, wherein the transcriptional regulator of apoptosis is selected from the group consisting of: SEQ ID NO: 39 and 40.

Claims 15-22 (canceled).

Claim 23 (withdrawn): A method for identifying a cell population responsive to treatment with an apoptosis modulatory agent, comprising:

- (a) contacting the cell population with a component selected from the group consisting of:
 - (1) anti-sense oligonucleotides directed against a transcriptional regulator of apoptosis;
 - (2) decoy oligonucleotides comprising a transcriptional regulatory of apoptosis binding site; and (3) polynucleotides encoding a transcriptional regulator of apoptosis; and
- (b) determining whether the level of apoptosis in the cell population is thereby modulated,

wherein the transcriptional regulator of apoptosis is a member of the Y-box nucleic acid binding family of polypeptides.

Application No. 10/028,415

Amendment and Reply to Office Action mailed November 10, 2005

Claim 24 (previously presented): The method of claim 28, wherein the decoy oligonucleotide comprises a sequence selected from the group consisting of: SEQ ID NO: 2 and 11.

Claim 25 (previously presented): The method of claim 14, wherein the cells are tumor cells.

Claims 26 and 27 (canceled).

Claim 28 (previously presented): A method for increasing apoptotic cell death in a population of cells, comprising reducing the amount of a transcriptional regulator of apoptosis available to bind to a target polynucleotide in the cells by contacting the population of cells with a decoy oligonucleotide comprising a transcriptional regulator of apoptosis binding site, wherein the transcriptional regulator of apoptosis comprises an amino acid sequence selected from the group consisting of: SEQ ID NO: 39 and 40 and wherein reducing the amount of the transcriptional regulator of apoptosis available to bind to the target polynucleotide leads to an increase in apoptotic cell death.

Claim 29 (previously presented): The method of claim 28, wherein the cells are tumor cells.

Claim 30 (previously presented): A method for increasing p53-mediated apoptosis in a cell population, comprising reducing the amount of a transcriptional regulator of apoptosis available to bind to a target polynucleotide in the cells by contacting the population of cells with a decoy oligonucleotide comprising a transcriptional regulator of apoptosis binding site, thereby increasing expression of p53 and increasing p53-mediated apoptosis, wherein the transcriptional regulator of apoptosis is selected from the group consisting of: SEQ ID NO: 39 and 40.

Claim 31 (previously presented): The method of claim 30, wherein the cells are tumor cells.

Application No. 10/028,415

Amendment and Reply to Office Action mailed November 10, 2005

Claim 32 (previously presented): The method of claim 30, wherein the decoy oligonucleotide is selected from the group consisting of: SEQ ID NO: 2 and 11.

Claim 33 (previously presented): The method of claim 6, wherein the anti-sense oligonucleotide is selected from the group consisting of: SEQ ID NO: 19-23 and 29-33.

Claim 34 (previously presented): The method of claim 14, wherein the anti-sense oligonucleotide is selected from the group consisting of: SEQ ID NO: 19-23 and 29-33.

Claim 35 (new): The method of claim 6, wherein the population of cells is contacted with at least two anti-sense oligonucleotides selected from the group consisting of: SEQ ID NO: 19-23 and 29-33.

Claim 36 (new): The method of claim 6, wherein the population of cells is contacted with at least five anti-sense oligonucleotides selected from the group consisting of: SEQ ID NO: 19-23 and 29-33.

Claim 37 (new): The method of claim 14, wherein the population of cells is contacted with at least two anti-sense oligonucleotides selected from the group consisting of: SEQ ID NO: 19-23 and 29-33.

Claim 38 (new): The method of claim 14, wherein the population of cells is contacted with at least five anti-sense oligonucleotides selected from the group consisting of: SEQ ID NO: 19-23 and 29-33.